Effects of evolocumab on low-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) by race and ethnicity: A meta-analysis of individual participant data from double-blind and open-label extension studies

Martha L. Daviglus, Keith C. Ferdinand, J. Antonio G. López, You Wu, Maria Laura Monsalvo, Carlos J. Rodriguez

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

BACKGROUND: Prevalence of cardiovascular disease risk factors and rates of atherosclerotic cardiovascular disease outcomes vary across racial/ethnic groups. This analysis examined the effects of evolocumab on LDL-C (low-density lipoprotein cholesterol) levels and LDL-C goals achievement by race/ethnicity. METHODS AND RESULTS: Data from 15 phase 2 and 3 studies of treatment with evolocumab versus placebo or ezetimibe were pooled (n=7669). Results were analyzed by participant clinical characteristics and by self-identified race/ethnicity. Key outcomes included percent change from baseline in LDL-C, achievement of LDL-C <70 mg/dL, and LDL-C reduction of ≥50% at 12 weeks and at 1 to 5 years. Across 12-week studies, mean percent change in LDL-C from baseline in evolocumab-treated participants was -52% to -59% for White and -46% to -67% for non-White participants, across clinical characteristics groups. LDL-C <70 mg/dL was achieved in 43% to 84% and 62% to 94% and LDL-C reduction of ≥50% in 63% to 78% and 58% to 86%, respectively. In 1- to 5-year studies, mean percent change in LDL-C was -46% to -52% for White and -49% to -55% for non-White participants. LDL-C <70 mg/dL was achieved in 53% to 84% and 66% to 77%, and LDL-C reduction of ≥50% in 53% to 67% and 58% to 68%, respectively. The treatment effect on mean percent change in LDL-C differed only in participants with type 2 diabetes mellitus, with a larger reduction in Asian participants. The qualitative interaction P values were nonsignificant, indicating consistent directionality of effect. CONCLUSIONS: Similar reduction in LDL-C levels with evolocumab was observed across racial/ethnic groups in 12-week and 1- to 5-year studies. Among those with diabetes mellitus, Asian participants had greater LDL-C reduction.

Original languageEnglish (US)
Article numbere016839
Pages (from-to)1-13
Number of pages13
JournalJournal of the American Heart Association
Volume10
Issue number1
DOIs
StatePublished - 2021

Keywords

  • Ethnicity
  • Evolocumab
  • Lipids and lipoproteins
  • Race

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Effects of evolocumab on low-density lipoprotein cholesterol, non-high density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a) by race and ethnicity: A meta-analysis of individual participant data from double-blind and open-label extension studies'. Together they form a unique fingerprint.

Cite this